7MO: A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Year: 2025
Type: article
Source: Journal of Thoracic Oncology
Institutions: Institut Català d'Oncologia, European Institute of Oncology, Asan Medical Center, Henry Ford Health, Henry Ford Hospital, Agostino Gemelli University Polyclinic, Monash Health, F. Hoffmann-La Roche AG, Genentech, Roche (United Kingdom), Royal Marsden NHS Foundation Trust, Royal Marsden Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Mesothelioma Applied Research Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, American Society of Clinical Oncology, Ariad Pharmaceuticals, Celgene, Novocure, Revolution Medicines, EQRx, Seagen, Eisai, Astellas Pharma, PharmaMar, National Institutes of Health, Genentech, Daiichi Sankyo Europe
OpenAlex ID: W4408978747
